CNS Pharmaceuticals Announces CEO Transition

About this update from Cns Pharmaceuticals, Inc.

[{"type":"text","content":"Industry veteran Rami Levin, MBA appointed as President & Chief Executive Officer","length":85,"tagName":"p"},{"type":"text","content":"HOUSTON, TX / ACCESS Newswire / December 17, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced John Climaco has stepped down as Chief Executive Officer of CNS Pharmaceuticals and Rami Levin, MBA, has been appointed as President & Chief Executive Officer.","length":473,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":368,"height":366,"url":"https://media.zenfs.com/en/accesswire.ca/ce71dcd771b965738ad9491d65d4bc9c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/g6APVFT4QgsxxvQkS3G9Ag--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTcwMTtjZj13ZWJw/https://media.zenfs.com/en/accesswire.ca/ce71dcd771b965738ad9491d65d4bc9c","width":368,"height":366}},"href":"https://app.accessnewswire.com/imagelibrary/47dcb9f6-dd95-403e-98e7-b465a079e731/1118481/picture1.jpg","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Mr. Levin brings nearly 30 years of global leadership experience across oncology, neurology, rare diseases, endocrinology, and cell and gene therapy, with a proven track record of scaling organizations, advancing late-stage clinical programs, and driving transformative value creation. Over the course of his career he has played a pivotal role in building organizations from the ground up, orchestrating 10-fold growth in sales and in teams, launching products globally and navigating the complexities of capital raising and business development both domestically and internationally.","length":585,"tagName":"p"},{"type":"text","content":""We are grateful to John and his dedicated service to CNS Pharmaceuticals and wish him all the best in his next endeavors. His passion for patients will continue to fuel CNS as it transitions to its next phase of evolution," said Faith Charles, Chair of the Board of Directors of CNS Pharmaceuticals. "Looking ahead, Rami is a seasoned biotech leader with a rare combination of scientific depth, commercial execu...

More updates from Cns Pharmaceuticals, Inc.